Brussels unveils new medicines law designed to reduce reliance on Asian producers through state aid and procurement incentives.
ℹ️ Озвучка браузером · студийный голос ИИ скоро
The European Union is moving to reshape its pharmaceutical supply chain through a new medicines law aimed at boosting domestic manufacturing and reducing dependence on China and India for critical drugs.
The initiative will use state aid and procurement preferences to incentivize drugmakers to produce more medicines within Europe. The move reflects broader EU strategy to strengthen supply chain resilience following pandemic-era shortages and geopolitical tensions.
The law represents a significant shift in European industrial policy, prioritizing sovereignty over cost considerations in the pharmaceutical sector. Implementation details remain under development as the EU seeks to balance competitiveness with strategic autonomy.